Cyclerion's 160% stock surge follows bold Alzheimer's-focused merger with Korsana

Cyclerion Therapeutics saw its shares surge by over 160% in pre-market trading after announcing a reverse merger with Korsana Biosciences. The deal will create a new company focused on Alzheimer's disease treatments, with a lead candidate already in development. The merged entity will operate under the name Korsana Biosciences and trade on Nasdaq as 'KRSA'. The merger will leave Cyclerion shareholders with just 1.5% ownership of the new company, while Korsana's investors retain 98.5%. The existing Korsana board will continue, with Tomas Kiselak from Fairmount taking the role of chairman. Jonathan Violin, Korsana's current CEO, will lead the combined organisation after the deal closes.

Cyclerion had been reviewing its strategic options before the merger. As a result, its early-stage programme for CYC-126 will likely be deprioritised once the transaction completes. Korsana's lead drug, KRSA-028, is a monoclonal antibody designed to target amyloid beta, a protein linked to Alzheimer's progression. Unlike traditional treatments, it is formulated for subcutaneous injection. Phase 1 trial results are due in mid-2027, with proof-of-concept data expected by the end of that year. Alzheimer's affects around 60 million people globally, highlighting the potential impact of the therapy. The company has already secured $380 million in private funding. Investors include Fairmount, Venrock Healthcare Capital Partners, J.P. Morgan, Janus Henderson, and Sanofi Ventures.

The merger positions Korsana Biosciences as a publicly traded company with a clear focus on Alzheimer's research. KRSA-028 remains the priority, with key clinical milestones set for 2027. The deal also marks a shift for Cyclerion, which will now play a minor role in the new entity's future.